Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Affymetrix Nixes Origin's Higher China-Backed Takeover Bid

publication date: Mar 29, 2016
Affymetrix decided to accept a lower takeover bid from Thermo Fisher Scientific, rather than a higher offer from former Affymetrix executives that was backed by SummitView Capital, a China private equity firm. Thermo Fisher offered $1.3 billion for Affymetrix while Origin, a special purpose vehicle formed by Centillion executives, upped its bid to $1.6 billion. Affymetrix said it felt the Origen offer was too risky. Although Origin disagreed with the assessment, it withdrew its takeover proposal. More details....

Stock Symbol: (NSDQ: AFFY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China